

## Cellogen Therapeutics develops indigenous bi-specific 3rd generation CAR T cells for cancer treatment

19 March 2025 | News

**To provide Indian and global patients with a safer and more effective alternative to existing CAR T cell therapies**



In a major breakthrough for India's biotech sector and cancer treatment, Delhi-based biotech startup Cellogen Therapeutics has secured regulatory approval for the patent of the world's first, indigenously developed Bi-Specific 3rd Generation Chimeric Antigen Receptor T (CAR T) cells. This milestone positions India as a key player in advanced cell and gene therapies and offers new hope to patients battling blood cancers.

Cellogen Therapeutics' pioneering CAR T cell technology represents a transformative advancement in cancer immunotherapy. Unlike conventional CAR T cell therapies, which target a single antigen, Cellogen's bi-specific platform engages two tumour-specific antigens simultaneously, enhancing treatment precision and reducing the risk of side effects such as cytokine release syndrome and neurotoxicity.

Cellogen Therapeutics has secured \$2 million in funding from NATCO Pharma Limited, which has acquired a 5.38% stake in the company. The startup is preparing for clinical trials in collaboration with Christian Medical College (CMC), Vellore. The trials will evaluate the safety and efficacy of the therapy, with Cellogen engaging regulatory authorities, healthcare institutions, and global partners to accelerate the treatment's availability.

The startup's research is supported by leading institutions, including the Council of Scientific & Industrial Research (CSIR), the Regional Centre for Biotechnology, the Institute of Genomics and Integrative Biology, and NATCO Pharma.